HUTU-80 - Cell Line (ID:50016)

HMS LINCS ID: 50016
Name: HUTU-80
Alternative Names: HuTu 80
LINCS ID: LCL-1150
Alternative ID: CLO_0004305
Parent Cell Line:
Reference Source: ATCC HTB-40
Organism: Homo sapiens
Organ: intestine
Tissue:
Cell Type: epithelial
Details of Cell Type:
Donor Sex: male
Donor Age:
Donor Ethnicity:
Donor Health Status:
Disease: DOID:10816, duodenum adenocarcinoma
Details of Disease:
Production Details:
Genetic Modification(s): none
Known Mutations:
Citation Information for Mutations: COSS907073
Verification Reference Profile: DNA Profile (STR, source: ATCC): Amelogenin: X,Y CSF1PO: 11,13 D13S317: 8,11 D16S539: 10,11 D5S818: 12,13 D7S820: 9,11 THO1: 7 TPOX: 9,11 vWA: 16,18
Growth Properties: adherent
Recommended Culture Conditions: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Subculturing: Remove and discard culture medium. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes). Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37 deg C to facilitate dispersal. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.Add appropriate aliquots of the cell suspension to new culture vessels. Incubate cultures at 37 deg C. Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:5 is recommended.
Relevant Citations:
Usage Note:
Comments:
Date Publicly Available: 2012-04-25
Most Recent Update: 2016-04-04

Batch Information for HMSL50016-1:

HMS LINCS Batch ID: 50016-1
Provider: Center for Molecular Therapeutics (CMT; Massachusetts General Hospital)
Provider Catalog ID: MGH-8074
Provider Batch ID:
Source Information: Obtained by Nathan Moerke (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes). CMT previously had obtained the cells from the Wellcome Trust Sanger Institute.
Date Received:
HMS QC Outcome:
Transient Modification(s):
Comments:
Date Publicly Available: 2012-04-25
Most Recent Update: 2015-06-29